StephanieJ.(Nahas)Nahas-GeigerMD
Neurology • Philadelphia, PAHeadache
Associate Professor, Neurology, Thomas Jefferson University
Dr. Nahas-Geiger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
900 Walnut St
Ste 200
Philadelphia, PA 19107Phone+1 215-955-2243Fax+1 215-955-2060- Is this information wrong?
Summary
- Dr. Stephanie Nahas is a neurologist with subspecialty certification in headache medicine practicing in Philadelphia, PA. She is affiliated with Thomas Jefferson University Hospitals. She received her medical degree from Rush Medical College in 2001, completed neurology residency in 2005, followed by fellowship in headache medicine, and has been on faculty at Jefferson since January 2017.
Education & Training
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Headache Medicine, 2005 - 2007- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Neurology, 2002 - 2005
Rush University Medical CenterInternship, Internal Medicine, 2001 - 2002
Rush Medical College of Rush University Medical CenterClass of 2001
Certifications & Licensure
FL State Medical License 2021 - Present
PA State Medical License 2002 - 2024- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Fellow American Headache Society
- Fellow American Academy of Neurology
Publications & Presentations
PubMed
- Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.Paul Rizzoli, Michael J Marmura, Jennifer Robblee, Jennifer McVige, Sara Sacco, Stephanie J Nahas, Jessica Ailani, Rosa De Abreu Ferreira, Julia Ma, Jonathan H Smith, ...> ;The Journal of Headache and Pain. 2024 Mar 11
- Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.Cristina Tassorelli, Kateryna Onishchenko, Rashmi B Halker Singh, Molly Duan, Laure Dupont-Benjamin, Matthew Hemstock, Corey Voller, Peter McAllister, Stephanie J Naha...> ;Cephalalgia. 2024 Feb 1
- 5 citationsRisk factors for migraine disease progression: a narrative review for a patient-centered approach.Dawn C Buse, Stephanie J Nahas, Gretchen E Tietjen, Vincent T Martin, Elin Löf, Thomas Brevig, Roger Cady, Hans-Christoph Diener, Lipton, R.> ;Journal of Neurology. 2023 Dec 1
- Join now to see all
Press Mentions
Migraine Nasal Spray with Novel Delivery System Gains FDA ApprovalSeptember 20th, 2021- Impel NeuroPharma Gains FDA Approval for First Therapeutic to Deliver DHE to Vascular-Rich Upper Nasal Space for Migraine Treatment Using POD TechnoloSeptember 4th, 2021
- FDA Approves DHE-Based Migraine Treatment TrudhesaSeptember 3rd, 2021
- Join now to see all
Hospital Affiliations
Thomas Jefferson University HospitalPhiladelphia, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
